<!DOCTYPE html>
<html lang="en">
	<head>
	    <title>RELISTOR</title>
	    <meta charset="utf-8">
	    <meta name="viewport" content="width=device-width, initial-scale=1">
	    <meta http-equiv="X-UA-Compatible" content="IE=edge">
	    <link rel="stylesheet" href="style/style.css">
	    <link href='https://fonts.googleapis.com/css?family=Lora' rel='stylesheet' type='text/css'>
	    <link href='https://fonts.googleapis.com/css?family=Lato:400,700' rel='stylesheet' type='text/css'>
	    <link href='https://fonts.googleapis.com/css?family=Roboto+Condensed:400,700' rel='stylesheet' type='text/css'>
	    <link rel="stylesheet" media="screen and (max-width: 868px) and (min-width: 736px)" href="style/stylefor868.css">
	    <link rel="stylesheet" media="screen and (max-width: 735px)" href="style/stylefor735.css">
	</head>
	<body>
		<div id="wrapper">
		  	<header id="header" class="clearfix">
		    	<div>
			        <p>
			            <img src="image/icosyringe@2x.png" alt = "">
			        </p>
			        <p>
			          RELISTOR &reg; <br /><span class="methylnaltrexone">(methylnaltrexone
						<br />bromide)</span>
			        </p>
		    	</div>

			    <nav id="nav-conteiner">
			        <ul>
				        <li> <a href="#wrapper" title="OVERVIEW"> <span class="icons icon-overview"> </span> OVERVIEW </a> </li>
				        <li> <a href="#clinicalInfo" title="CLINICAL INFORMATION"> <span class="icons icon-clinical"> </span> CLINICAL INFORMATION </a> </li>
				        <li> <a href="#drugMono" title="DRUG MONOGRAPH"> <span class="icons icon-drug"> </span> DRUG MONOGRAPH </a> </li>
			        </ul>
			    </nav>
		    </header>

		    <div class="styleFofSector  backgrImg" > <!--Логотип и изображение(шприц) и описание-->
		        <div class="logoImage">
		        	<img src="image/logo-relistor@3x.png" alt="Relistor methylnaltrexone bromide subcutaneous injection">
		        </div>
		        <div class="photoSyring">
		        	<img src="image/photo-syringe@3x.png" alt="">
		        </div>
		        <div>
		        	<h1>
		        		RELISTOR helps provide reliable and rapid relief from opioid-induced conspiration (OIC)<sup>1</sup>
		        	</h1>
		        	<p>
			          	In a clinical study of RELISTOR (n=150) for the treatment of OIC in adult patients with chronic non-cancer pain:
			        </p>  
			        <ul class="itemNoMargin items">
			          	<li><span>  6 out of 10 RELISTOR patients (n=88) had at least 3 Spontaneous Bowel Movements (SBMs) per week </span> </li>
			          	<li><span>One-third of RELISTOR patients experienced an SBM within 4 hours of their first dose</span></li>
			        </ul>
		        </div>
		    </div>

		    <h2 id="clinicalInfo">
		    	OPIOID-INDUCED CONSTIPATION MAY HAVE A BIGGER IMPACT THAN YOU MIGHT REALIZE
		    </h2>
		    <div class="styleFofSector">
		    	<ul class="items">
		        	<li><span>Opioids used to manage chronic non-cancer pain can cause constipation and
					discomfort in the gastrointestinal (GI) tract, known as OIC<sup>2,3</sup></span></li>
		        	<li><span>When traditional therapies and lifestyle changes provide limited relief, your patients
					may be experiencing OIC<sup>3</sup></span></li>
		    	</ul>

			    <div class="clearfix">
			        <div id="circlePercent">            <!--41%-->
			        	41<span>%</span>
			        	<img src="image/mask@3x.png"alt="">
			        </div>
			        <div class="rightGrafComent">
			        	<h3>
			        		OIC is Common and Persistent<sup>2</sup>
		        		</h3>
			        	<p class="firstTextInBlock">
			            	41% of patients taking opioids for chronic non-cancer pain reported being constipated<sup>*</sup>
			        	</p>
			        	<p class="footnote">
			            	<span><sup> * </sup></span> Results based on a systematic review including 673 surveyed patients from 8 trials designed to assess the safety and efficacy of opioid therapy for chronic pain.
			        	</p>
			        </div>
			    </div>

		    	<div class="clearfix">
    				<div id="humanStat">
		        		<img src="image/humans@2x.png" alt="">
		        	</div>
		    		<div class="leftGrafComent">
						<h3>
		    				Pain Management May be Compromised by OIC<sup>3</sup>
		    			</h3>
			    		<p class="firstTextInBlock">
			        		Effect on pain management
				        </p>  
				        <ul class="items">
			        		<li><span>Approximately one-third of patients on daily opioids reported altering their opioid dose to ease a bowel movement (BM)<sup>&#8224;</sup> </span> </li>
			        		<li><span>92% of these patients reported increased pain after doing so</span> </li>
			        	</ul>
				        <p class="footnote">
				        	<span><sup> &#8224; </sup></span> Report is based on a survey of 322 chronic pain patients. Participants altered their oral opioid treatment by skipping a dose, decreasing the dose, or stopping opioid treatment to ease a BM.
				        </p>
			        </div>
			    </div>
		    </div>

		    <h2 id="drugMono">
		    	RELISTOR&reg; (methylnaltrexone bromide) SUBCUTANEOUS INJECTION HELPS PROVIDE RELIABLE AND RAPID RELIEF <br/>FROM OPIOID-INDUCED CONSTIPATION
		    </h2>
		    <div class="styleFofSector">
		    	<h3>
		    		IN ADULT PATIENTS WITH OIC ON OPIOIDS FOR CHRONIC <br/>NON-CANCER PAIN
		    	</h3>
		    	<div>
		    		<p class="firstTextInBlock">
          				IN CLINICAL STUDIES: 
        			</p>
        			<ul class="items">
            			<li><span>62% and 48% of patients treated with RELISTOR had a BM within 4 hours of the first injection in 2 studies<sup>1,4</sup></span></li>
            			<li><span>Approximately 30% of patients reported laxation within 30 minutes of a dose of RELISTOR<sup>1,||</sup></span></li>
          			</ul>
        			<p class="footnote">
          				<span><sup>||</sup></span> SBM occurring without the use of rescue laxatives. 
        			</p>
		    	</div>
		    </div>

    		<div class="styleFofSector">
        		<h4>Study Designs</h4>
        		<ul class="items nestedItem">
          			<li><span>Patients with chronic non-cancer pain</span>
            			<ul>
              				<li>
                				<span>In a 4-week, double-blind, randomized, placebo-controlled phase 3 study, the efficacy of RELISTOR was evaluated in 312 patients (150 RELISTOR 12 mg once daily, 162 placebo) with chronic non-cancer pain for which they were taking opiates. All patients had OIC, defined as &lt; 3 SBMs per week and &ge;1 additional symptom of constipation<sup>1</sup> </span>
              				</li>
            			</ul>
          			</li>
          			<li><span>Patients with advanced illness</span>
            			<ul>
              				<li>
                				<span>One study was a multicenter, double-blind, randomized, placebo-controlled study, in which the efficacy of RELISTOR was evaluated in 154 patients <br/> (102 RELISTOR, 52 placebo) with advanced illness on palliative care with OIC<sup>1</sup></span> 
              				</li>
              				<li>
                				<span>Another study was a 2-week, double-blind, randomized, placebo-controlled trial followed by a subsequent 3-month, open-label extension study. The efficacy of RELISTOR was evaluated in 133 patients (62 RELISTOR, 71 placebo) with terminal disease<sup>1</sup> </span>
              				</li>
            			</ul>
          			</li>
        		</ul>
      		</div>
	    </div>
	</body>
</html>